References
- Végran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S, Boidot R.. Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Forthcoming http://dx.doi.org/10.1158/0008-5472.CAN-13-0036
- Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314:902 - 7; http://dx.doi.org/10.1016/j.bbrc.2003.12.178; PMID: 14741722
- Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rödel F, Klein-Hitpass L, Kovács AF, Döring C, Hansmann ML, et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007; 6:1502 - 9; http://dx.doi.org/10.4161/cc.6.12.4305; PMID: 17582222
- Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res 2010; 18:541 - 7; http://dx.doi.org/10.3727/096504010X12767359113848; PMID: 20939430
- Fregni G, Perier A, Avril MF, Caignard A. NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies. Oncoimmunology 2012; 1:38 - 47; http://dx.doi.org/10.4161/onci.1.1.18312; PMID: 22720210
- Boidot R, Végran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009; 23:285 - 91; PMID: 19148555
- Végran F, Boidot R, Bonnetain F, Cadouot M, Chevrier S, Lizard-Nacol S. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocr Relat Cancer 2011; 18:783 - 92; http://dx.doi.org/10.1530/ERC-11-0105; PMID: 21878572